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Introduction
Eph receptor tyrosine kinases (Eph RTKs) and cognate cell 
surface ephrin ligands orchestrate patterns of cellular organi-
zation by arranging cell–cell contacts through control of adhe-
sive and contractile cell functions (Lackmann and Boyd, 2008; 
Pasquale,  2008). They  assemble  multivalent  (Himanen  et  al., 
2001) signaling clusters, which initiate Eph receptor forward 
signaling  via  conserved  juxtamembrane  and  activation  loop 
phosphotyrosines (PYs; Wybenga-Groot et al., 2001), and re-
verse signaling by clustered ephrins (Pasquale, 2008). The over-
all signal strength largely determines if cells respond to ephrin 
contact by repulsion or by adhesion (Holmberg and Frisén, 2002;   
Wimmer-Kleikamp et al., 2008). Similar to other RTKs, specific 
protein tyrosine phosphatases (PTPs) are thought to control Eph 
activation and shape cellular responses ensuing from contacts 
between Eph- and ephrin-expressing cells (Lackmann and Boyd, 
2008).  Consistent  with  this  notion,  PTPRO  controls  EphA4 
phosphorylation in retinal ganglion cells and modulates their 
sensitivity to ephrin contact (Shintani et al., 2006), and EphB2 
activation is controlled by the leukocyte common antigen- 
related tyrosine phosphatase receptor (LAR-1; Poliakov et al., 
2008), whereas elevated PTP activity in EphA3-overexpressing 
leukemia cells shifts the response to ephrinA5 from cell–cell 
repulsion to adhesion (Wimmer-Kleikamp et al., 2008). More-
over, insulin secretion from pancreatic  cell granules, triggered 
by glucose-induced elevation of PTP activity, attenuates EphA5 
forward and promotes ephrinA reverse signaling (Konstantinova 
et al., 2007).
PTP1B is a prototypic nonreceptor tyrosine phosphatase, 
with established roles as a negative regulator of several RTKs, 
including the receptors for insulin, epidermal growth factor, and 
E
ph receptors orchestrate cell positioning during nor-
mal and oncogenic development. Their function is 
spatially and temporally controlled by protein tyro-
sine phosphatases (PTPs), but the underlying mechanisms 
are unclear and the identity of most regulatory PTPs are 
unknown. We demonstrate here that PTP1B governs sig-
naling and biological activity of EphA3. Changes in PTP1B 
expression significantly affect duration and amplitude of 
EphA3 phosphorylation and biological function, whereas 
confocal fluorescence lifetime imaging microscopy (FLIM) 
reveals direct interactions between PTP1B and EphA3   
before ligand-stimulated receptor internalization and, 
subsequently, on endosomes. Moreover, overexpression 
of wild-type (w/t) PTP1B and the [D-A] substrate–trapping 
mutant decelerate ephrin-induced EphA3 trafficking in a 
dose-dependent manner, which reveals its role in control-
ling EphA3 cell surface concentration. Furthermore, we   
provide evidence that in areas of Eph/ephrin-mediated   
cell–cell  contacts,  the  EphA3–PTP1B  interaction  can   
occur directly at the plasma membrane. Our studies for 
the first time provide molecular, mechanistic, and func-
tional insights into the role of PTP1B controlling Eph/ 
ephrin-facilitated cellular interactions.
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Figure 1.  PTP1B controls ephrin-induced phosphorylation of EphA3. (A) ­EphA3 immunoprecipitates and whole cell lysates from GFP­PTP1B,   
GFP­PTP1B­[D­A], or control vector­transfected EphA3/HEK293T cells, treated with ephrinA5­Fc, were analyzed by Western blotting with antibodies as indicated. 
The ratio of phosphorylated EphA3/total EphA3 (n = 3) was estimated (densitometry); mean ± SE are shown (error bars). (B) ­EphA3 immunoprecipitates 1191 EphA3 regulation by PTP1B • Nievergall et al.
and cell lysates of PTP1B, PTP1B­[D­A], or control vector (pMT2)­transfected 22Rv1 prostate carcinoma cells, with or without 10 min of ephrinA5 stimulation, 
were immunoblotted with the appropriate antibodies. Molecular mass standards are indicated next to the gel blots in kilodaltons. (C) EphrinA5­induced 
EphA3 phosphorylation in ­EphA3 immunoprecipitates from EphA3/HEK293T cells transfected with EGFP (control) vector, GFP­PTP1B, GFP­LMW­PTP, 
or GFP­SHP2, was quantified by densitometry analysis of Western blots (n = 3); mean PY­EphA3 levels, normalized to the EGFP­transfected control, ±SE 
are shown (error bars; ***, P < 0.001). (D) EphrinA5­induced EphA3 phosphorylation was monitored in PTP1B w/t and in control vector­transfected 
COS7 cells by confocal FLIM using YFP­EphA3 as fluorescence donor and Cy3.5­labeled PY72 as an acceptor. The YFP fluorescence lifetime maps are 
illustrated together with confocal micrographs revealing YFP­EphA3, PY, and PTP1B, the latter detected with labeled ­PY (
Cy3.5PY72) and ­PTP1B (
Cy5FG6) 
antibodies. Endogenous PTP1B (top) is shown at a higher display setting compared with recombinant w/t PTP1B (bottom). (E) The relative fraction () of 
membrane­proximal activated EphA3 receptors in PTP1B­overexpressing and control cells was calculated pixel­by­pixel from the ratio of the amplitude of the 
short lifetime component and the sum of the two amplitudes (n = 40 cells); mean ± SE are shown (error bars; **, P < 0.005). (F) The correlation between 
EphA3­YFP lifetimes (averaged across the whole cell) and the PTP1B expression level (determined from the fluorescence intensity of Cy5­­PTP1B staining) 
is illustrated, where increased lifetime indicates decreased EphA3 phosphorylation. Each data point represents measurements from an individual cell.
 
platelet-derived growth factor  (Bourdeau et al., 2005; Tonks, 
2006), and as a positive modulator of integrin and cadherin signaling 
(Burridge et al., 2006; Sallee et al., 2006). Within cells, PTP1B 
is anchored to the cytoplasmic face of the ER (Frangioni et al., 
1992) so that its interaction with transmembrane or membrane-
proximal substrates, as well as the timing and site of their de-
phosphorylation, poses a conceptual dilemma. Recent findings 
provide strong evidence for dynamic, spatially and temporally 
controlled interactions between PTP1B and its transmembrane 
or membrane-associated substrates, whereby dephosphoryla-
tion by PTP1B occurs when endocytosed RTKs transit past the   
ER (Haj et al., 2002; Boute et al., 2003). Other studies, however, 
suggest that PTP1B contacts transmembrane receptors and 
cell–matrix adhesion sites directly (Hernández et al., 2006; 
Anderie et al., 2007), and a recent study suggested the existence 
of microtubule-dependent positioning of ER-bound PTP1B to 
the periphery of growth cones that is stabilized by cell–cell con-
tacts (Fuentes and Arregui, 2009).
We now demonstrate that rapid recruitment of PTP1B 
to the cell surface controls activity, trafficking, and function 
of  EphA3  in  cell  contact  with  ephrinA5-expressing  cells.   
We  show  that  EphA3  phosphorylation  and  endocytosis  is 
tightly controlled by PTP1B in normal and cancer cell lines, 
consequently regulating downstream cell morphological re-
sponses. Our study provides the first comprehensive evidence 
for a central role of PTP1B in controlling Eph receptor func-
tion by modulating the amplitude and biological consequences 
of Eph/ephrin signaling.
Results
PTP1B negatively regulates ephrinA5-
induced EphA3 phosphorylation
We reported previously that EphA3 kinase activity and bio-
logical functions are tightly controlled by tyrosine phosphatase 
activity, although PTPs implicated in Eph signaling, including 
low molecular weight PTP (LMW-PTP) and Src homology 2   
domain-containing PTP 2 (SHP2), appeared not to affect EphA3 
phosphorylation directly (Wimmer-Kleikamp et al., 2008). How-
ever, biotin-iodoacetamide labeling of reactive oxygen-sensitive 
cysteine residues (Kim et al., 2000) in whole cell lysates from 
ephrinA5-stimulated cells identified a Mr 45–50-kD protein as 
a potential PTP that is transiently inactivated by reactive oxygen 
species (ROS; Tonks, 2005) during EphA3 signaling (unpub-
lished data). A matching molecular weight and circumstantial   
evidence suggesting that the EphA3 activation loop tyrosine was 
a potential substrate (Mertins et al., 2008) prompted us to explore 
PTP1B for its potential role in controlling EphA3 signaling.
We first tested the impact of PTP1B overexpression on 
EphA3  activation  in  EphA3-positive  HEK293T  (EphA3/
HEK293T) cells (Fig. 1 A) and in 22Rv1 prostate carcinoma 
cells with high endogenous EphA3 expression (Fig. 1 B).   
In both cell lines, expression of wild-type (w/t) PTP1B signifi-
cantly  reduced  ephrinA5-induced  EphA3  phosphorylation   
(Fig. 1, A–C; and Fig. S1 B), whereas overexpression of the 
catalytically impaired substrate trapping mutant PTP1B-[D-A] 
(Flint et al., 1997) enhanced the duration (Fig. 1 A) and am-
plitude (Fig. 1, A and B) of EphA3 phosphorylation in stimu-
lated and nonstimulated cells. By comparison, overexpression 
of T cell PTP (TC-PTP), a phosphatase with high structural 
and functional homology to PTP1B, had only a moderate effect 
on EphA3 phosphorylation in stimulated 22Rv1 cells (Fig. S1,   
A and B). Similarly, LMW-PTP and SHP2, which had been im-
plicated in Eph signaling (Stein et al., 1998; Miao et al., 2000; 
Parri et al., 2005), did not affect ephrin-induced EphA3 phos-
phorylation in EphA3/HEK293T cells (Fig. 1 C).
We next examined PTP1B-controlled EphA3 phosphory-
lation in whole cells using confocal fluorescence lifetime im-
aging microscopy (FLIM) to map the energy transfer between 
YFP-tagged  EphA3  as  the  fluorescence  energy  donor  and 
Cy3.5-tagged anti-PY (-PY) antibody (Reynolds et al., 2003) 
as the fluorescence acceptor. As anticipated, ephrinA5 stimula-
tion yielded notable Förster resonance energy transfer (FRET) 
at the plasma membrane (PM) and in membrane-proximal vesi-
cles (Fig. 1 D). PY-EphA3 was also present in perinuclear com-
partments of stimulated and nonstimulated cells (Fig. S1 C), 
which likely reflects cytosolic accumulation of activated recep-
tors present because of transient overexpression. Transfection 
with w/t PTP1B markedly reduced FRET (i.e., increased the YFP 
fluorescence lifetime) in all cellular compartments (Fig. 1 D 
and Fig. S1 D), which indicates a consistent reduction in levels 
of ephrinA5-activated EphA3 receptors (Fig. 1 E). A positive 
correlation between increasing PTP1B expression (measured as 
Cy5--PTP1B intensity) and increasing YFP fluorescence life-
times (which is indicative of reduced FRET; Fig. 1 F) implies 
that FRET is a genuine measure of PTP1B-catalyzed EphA3 de-
phosphorylation, which we observed consistently across whole 
cells or within relevant PM compartments (Fig. S1 D).
We  further  assessed  if  PTP1B  counteracts  EphA3  sig-
naling  by  silencing  PTP1B  expression  in  EphA3/HEK293T 
and in 22Rv1 prostate carcinoma cells using small-hairpin RNA 
(shRNA). In clones from both cell lines, notably reduced PTP1B   JCB • VOLUME 191 • NUMBER 6 • 2010   1192
expression coincided with elevated ephrinA5-induced EphA3 
phosphorylation  (Fig.  2,  A  and  B).  Although  basal  EphA3 
phosphorylation  was  only  moderately  elevated  in  EphA3/
HEK293T cells, we noted a prominent increase in duration 
and amplitude of phosphorylation in both cell lines (Fig. 2,   
A and B). Likewise, in PTP1B
/ mouse embryonic fibroblasts 
(MEFs) engineered to stably express EphA3, ephrin-induced 
EphA3 phosphorylation was notably enhanced and prolonged 
compared with their PTP1B-reconstituted counterparts (Fig. 2 C).   
EphA3-transfected w/t MEFs with comparable levels of endog-
enous PTP1B responded to ephrinA5 stimulation with markedly 
increased phosphorylation, whereas transient EphA3 expres-
sion in PTP1B
/ MEFs, in addition, triggered EphA3 hyper-
phosphorylation even without ephrinA5 activation (Fig. 2 D). 
This deregulated EphA3 activation likely reflects an acute lack 
of PTP control over EphA3 phosphorylation in transiently trans-
fected cells, which lack compensatory mechanisms that would 
be active in stably transfected cells (Fig. 2 C).
Association of PTP1B-[D-A] with  
EphA3 relies on intact tyrosine 
phosphorylation sites
Our findings prompted us to study the interaction between   
YFP-EphA3 and dHcRed-PTP1B-[D-A] and map the subcellu-
lar location of PTP1B recruitment in intact cells using confocal   
FLIM. FRET-induced low YFP-EphA3 donor lifetimes in intracel-
lular and in some PM-proximal compartments of nonstimulated 
cells (Fig. 3 A, middle, yellow-orange) imply that EphA3 inter-
acts directly with PTP1B-[D-A], even in the absence of ephrin. 
Stimulation with ephrinA5 resulted in a dramatic increase in 
PM-proximal FRET, particularly in areas of cell–cell contact 
(Fig. 3 A, bottom), which confirmed prominent PTP1B-[D-A] 
recruitment to ligand-activated EphA3. Also, live-cell FLIM 
during ephrinA5-triggered EphA3 activation revealed a gradual 
decrease in YFP lifetimes (increased FRET) over 30 min, which 
confirmed the continued recruitment of PTP1B-[D-A] over and 
above the basal association observed in nonstimulated cells   
(Fig. 3 B and Fig. S2 A). Interestingly, we also detected FRET in 
cells expressing dHcRed-PTP1B-[D-A] and GFP-tagged EphB2, 
which suggests that PTP1B may also control phosphorylation 
of EphB receptors, whereas a [C-S] substrate–trapping mutant 
of LMW-PTP used in a control experiment appeared not to   
associate with EphA3 directly (Fig. S2 B).
To assess the protein domains and/or interaction motifs re-
sponsible for the interaction between EphA3 and PTP1B-[D-A],   
we performed coimmunoprecipitation analysis of various mutant 
EphA3 proteins: mutants lacking the essential juxtamembrane 
and activation loop tyrosines (3Y-F), the cytoplasmic domain 
(570), or kinase domain (621) showed no detectable tyrosine   
phosphorylation and marginal ([3YF] mutant) or no capacity to   
associate with PTP1B-[D-A] (Fig. 3 C). In agreement, we did 
not observe FRET in PTP1B
/ MEFs coexpressing GFP- 
EphA3-[3Y-F] and dHcRed-PTP1B-[D-A] (Fig. S2 C), which to-
gether suggest that the presence of the EphA3 consensus tyrosine   
phosphorylation sites (Wybenga-Groot et al., 2001) is a prerequi-
site for the PTP1B-[D-A]/EphA3 association. Although truncation 
of the PDZ binding motif (K997) did not affect phosphorylation 
Figure 2.  Abrogated PTP1B expression causes enhanced and prolonged 
EphA3 activation. (A and B) EphA3/HEK293Ts (A) and 22Rv1 cells 
(B), stably transfected with PTP1B­shRNA– or nontarget control vector– 
containing lentiviral transduction particles, were subjected to ephrinA5 
stimulation. ­EphA3 immunoprecipitates and whole cell lysates were ex­
amined by immunoblotting with the appropriate antibodies. Densitometry 
quantifies  EphA3  phosphorylation  relative  to  total  EphA3  expression. 
Data are representative of at least five (A) and three (B) independent ex­
periments, respectively. (C) The time course of ephrinA5­induced EphA3 
phosphorylation in PTP1B­reconstituted or parental PTP1B
/ MEFs, both 
stably transfected with EphA3, was assessed by immunoblotting of anti­
EphA3  immunoprecipitates  using  antibodies  against  EphA3,  PY,  and 
PTP1B, as indicated. Densitometry quantifies relative EphA3 phosphory­
lation, which is representative of two experimental repeats. The black 
line indicates that intervening lanes have been spliced out. (D) PTP1B
/ 
MEFs with or without reconstitution with w/t PTP1B and w/t MEFs were 
transiently  transfected  with  EphA3.  ­EphA3  immunoprecipitates  from 
ephrinA5­stimulated or nonstimulated cells were analyzed by Western 
blot analysis using antibodies against PY­EphA3, EphA3, and PTP1B as 
indicated. Molecular mass standards are indicated next to the gel blots 
in kilodaltons.1193 EphA3 regulation by PTP1B • Nievergall et al.
cells, the question arises if the ER-resident PTP1B can contact 
EphA3 that is already at the cell surface. To address this notion, 
we  cotransfected  dHcRed-PTP1B-[D-A]  and  YFP-EphA3 
into COS7 cells and analyzed their interaction with ephrinA5-
expressing HEK293T cells. FLIM revealed, in addition to obvi-
ous pools of the colocalized proteins in the cytosol, conspicuous 
clusters of EphA3-associated PTP1B-[D-A] clearly marking PM 
interfaces with ephrinA5-expressing cells (Fig. 4 A, yellow   
arrows). Using Cy3.5-labeled -PY antibody as a fluorescence   
acceptor, FLIM suggested that these prominent sites of EphA3/
PTP1B-[D-A] association corresponded with sites of marked 
or PTP1B-[D-A] association, by comparison both were reduced 
in the EphA3 sterile alpha motif (SAM) domain truncation mu-
tant (K880; Fig. 3 C), which is in line with a potential role of the 
SAM domain in stabilizing EphA3 signaling complexes during 
activation and downstream signaling (Stapleton et al., 1999).
PTP1B directly interacts with  
activated EphA3 at contacts to  
ephrinA5-expressing cells
Considering  that  physiological  Eph-ephrin  signaling  is  only 
triggered at sites of contact between Eph and ephrin-expressing   
Figure 3.  The interaction between PTP1B and EphA3 is kinase dependent. (A) The association between YFP­EphA3 and dHcRed­PTP1B­[D­A] in untreated 
or ephrinA5­stimulated COS7 cells was analyzed by confocal FLIM. Confocal micrographs of YFP­EphA3 (donor) fluorescence and the YFP fluorescence 
lifetime maps are shown. The boxed area in the bottom right is shown at higher magnification. (B) COS7 cells transfected with YFP­EphA3 and dHcRed­
PTP1B­[D­A] were stimulated with ephrinA5, and live cells were analyzed by FLIM. The distribution of YFP fluorescence lifetimes at various time points during 
stimulation is plotted. The corresponding confocal images and lifetime maps are presented in Fig. S4 A. (C) NG108 cells, lacking endogenous Ephs (Elowe 
et al., 2001), cotransfected with cDNAs encoding GFP­PTP1B­[D­A] and w/t or mutant EphA3 (containing tyrosine­replacement or truncation mutants as 
indicated) were stimulated with ephrinA5 before lysis, ­EphA3 immunoprecipitation, and Western blot analysis with antibodies as indicated. The black 
line indicates that intervening lanes have been spliced out. Molecular mass standards are indicated next to the gel blots in kilodaltons.JCB • VOLUME 191 • NUMBER 6 • 2010   1194
(Fig. 5 A), but cannot be shed by EphA3-associated ADAM10 
(Janes et al., 2005). This trapping of activated EphA3 at the cell 
surface effectively prevents ephrin-induced endocytosis and   
allows  monitoring  protein–protein  interactions  that  normally 
may occur shortly before or during EphA3 internalization. Stain-
ing of intact (nonpermeabilized) cells with -EphA3 monoclonal 
antibodies (mAb) and their analysis by confocal microscopy 
revealed coinciding EphA3 and GFP-PTP1B-[D-A]–associated 
fluorescence accumulating around many of the SA beads, a   
pattern that was absent in control cells not expressing biotin 
ligase (BirA) and thus lacking the capacity to tether SA beads 
(Fig. 5 B). By comparison, incubation of APN-EphA3/HEK293T 
cells with Alexa Fluor 594–ephrinA5–Fc–coated beads yielded 
notable,  but  considerably  weaker  GFP-PTP1B–associated   
fluorescence that is directly associated with the beads (Fig. 5 C), 
which  confirmed  that  rapid  and  continuous  ephrin  cleav-
age (Janes et al., 2005) and endocytosis of activated EphA3   
EphA3 phosphorylation (Fig. 4 B). Of note, although FRET was   
not apparent in cells expressing w/t dHcRed-PTP1B as a fluores-
cence acceptor, their contacts with ephrinA5 cells were still lined 
with pronounced EphA3 accumulation (Fig. 4 A, bottom, open   
arrows). Together, these findings suggest that PTP1B is indeed 
recruited to ephrinA5–EphA3 complexes, which tether interact-
ing cells; however, this analysis does not discern if the contact 
between PTP1B-[D-A] and activated EphA3 occurs at the PM 
or on PM-proximal, early endosomal vesicles.
To address this question, we imaged PTP1B-[D-A] sub-
strate trapping in COS 7 cells coexpressing EphA3 that is 
tagged on its N terminus with a biotin acceptor peptide (APN), 
and Escherichia coli biotin ligase (BirA; Howarth and Ting, 
2008). EphA3 in these APN-EphA3/BirA COS 7 cells is con-
stitutively biotinylated so that streptavidin (SA) conjugated 
to beads can be used as surface-tethered agonist that clusters 
(Janes et al., 2009) and activates the biotinylated APN-EphA3 
Figure 4.  PTP1B is recruited to sites of Eph/ephrin contact. (A) COS7 cells overexpressing YFP­EphA3 and dHcRed­PTP1B­[D­A] or w/t dHcRed­PTP1B 
were co­cultured (20 min) with ephrinA5/HEK293T cells and analyzed by FLIM to monitor direct interactions between EphA3 and PTP1B. Confocal images 
and YFP­EphA3 lifetime maps are shown. White broken lines mark the boundaries of EphA3­expressing cells; orange dotted lines mark those of ephrinA5 
cells. Yellow arrows indicate EphA3­associated PTP1B­[D­A] and FRET at PM interfaces with ephrinA5­expressing cells. Open arrows indicate accumulated 
EphA3 in w/t dHcRed­PTP1B–expressing cells at sites of contact with ephrinA5 cells. (B) Co­cultures (20 min) between YFP­EphA3 expressing COS7 cells 
and ephrinA5­expressing HEK/293T cells were fixed, permeabilized, and stained with Cy3.5­tagged ­PY antibody to monitor EphA3 phosphorylation 
by using FRET between YFP­EphA3 and the Cy3.5­­PY antibody. Dotted lines are as described in A. Yellow arrows indicate EphA3­associated Cy3.5­­PY 
antibody and FRET at sites of marked EphA3 phosphorylation.1195 EphA3 regulation by PTP1B • Nievergall et al.
previously (Lawrenson et al., 2002), stimulation of EphA3/
HEK293T cells with preclustered ephrinA5-Fc caused pro-
nounced  contraction  of  the  actin  cytoskeleton  (Fig.  6 A,   
EGFP ctrl), which is considered to be the prerequisite for 
cell–cell repulsion. Estimation of the cellular footprint from 
the actin-associated fluorescence before and after ephrinA5 
treatment revealed that PTP1B overexpression significantly 
attenuates cytoskeletal contraction in ephrinA5-stimulated cells 
(Fig. 6, A–C, PTP1B w/t). Notably, cells with high exogenous 
PTP1B remained stretched out (Fig. 6 A, closed arrowheads),   
whereas neighboring cells with low/undetectable GFP-PTP1B 
(as indicated by fluorescent cytosolic vesicles) prevents its accu-
mulation on the beads. Collectively, these data unambiguously 
demonstrate the capacity of PTP1B to associate with activated 
EphA3 at regions of the cell surface that are in contact with a 
(cell) surface-bound agonist.
Eph/ephrin-mediated cell contraction and 
cell sorting is modulated by PTP1B
We next tested if modulating PTP1B expression by cDNA trans-
fection or stable shRNA-mediated silencing would impact on 
cell biological responses to EphA3 signaling. As described 
Figure 5.  PTP1B interacts with EphA3 at the cell surface. (A) EphA3 clustering by SA beads provokes tyrosine phosphorylation. COS7 cells, cotransfected 
with APN­EphA3 and BirA, were stimulated with SA Dynabeads. Tyrosine phosphorylation was evaluated by confocal microscopy of fixed and permeabil­
ized cells stained with 
Cy3.5­PY (PY72) antibodies. SA Dynabeads appear blue in the merged image; yellow arrows mark beads with ­PY association.   
(B) COS7 cells, cotransfected with GFP­PTP1B­[D­A], APN­EphA3, and TM­BirA (as indicated), were stimulated with SA Dynabeads. Cell surface EphA3 was 
labeled on intact cells with IIIA4 ­EphA3 mAb and detected with Alexa Fluor 546–labeled secondary antibodies by confocal microscopy. Yellow arrows 
mark SA Dynabeads where PTP1B/EphA3 colocalization is apparent. (C) GFP­PTP1B­[D­A] and EphA3­transfected COS7 cells were stimulated with Alexa 
Fluor 594–ephrinA5–Fc–coated Protein A Dynabeads, then fixed and analyzed by confocal microscopy. White dotted lines mark cell boundaries from 
bright­field images.JCB • VOLUME 191 • NUMBER 6 • 2010   1196
and ephrin expression. To this end, we analyzed co-cultures of 
U251 glioblastoma cells and HEK293 cells with demonstrable 
endogenous expression of Eph and ephrin, as shown by binding 
of ephrinA5-Fc and EphA3-Fc, respectively (Fig. 7 A), and of 
PTP1B (Fig. 7 D). As expected, fluorescent-labeled HEK293 
cells were segregated into distinct, partially interconnected cell 
clusters that are bordered by U251 cells (Fig. 7 B, ctrl). Treat-
ment with PTP1B inhibitor tightened these clusters, as indi-
cated by reduced dispersion of fluorescence intensity peaks in 
corresponding 2D and 3D contour maps (Fig. 7 B, bottom; and   
Fig. S3, A and B), a significantly higher fluorescence intensity per 
were contracted. However, silencing of PTP1B significantly 
enhanced  ephrin-induced  cell  contraction  (Fig.  6,  A–C, 
PTP1B shRNA).
We assessed the role of PTP1B in regulating EphA3 func-
tion to facilitate cell–cell repulsion from ephrin-expressing cells 
in a more physiological setting by adopting a cell co-culture 
system that is regarded as a model of Eph/ephrin-mediated cell 
sorting (Poliakov et al., 2008; Jørgensen et al., 2009) during 
tissue boundary formation (Mellitzer et al., 1999). To avoid 
uncontrolled effects due to overexpression of exogenous pro-
teins, we selected for this assay cell lines with endogenous Eph 
Figure 6.  Modulation of PTP1B expression alters ephrin-induced cell contraction. (A) EphA3/HEK293T cells stably transfected with PTP1B­shRNA and 
nontarget control shRNA EphA3/HEK293T cells transiently expressing GFP alone (control) or w/t GFP­PTP1B were stimulated with ephrinA5 (40 min) or left 
untreated. Cell morphology, observed by Alexa Fluor 647–phalloidin staining and GFP­(PTP1B) expression, was analyzed by confocal microscopy. Closed 
and open arrowheads mark cells with high and low PTP1B levels, respectively. (B) Thresholded fluorescence area of Alexa Fluor 647–phalloidin staining 
was determined in 10 low­magnification images per condition of the experiment shown in A and plotted as mean ± SE (error bars; ***, P < 0.001).   
(C) Relative ephrinA5­induced cell contraction was estimated from the ratio of the actin­associated fluorescence footprint in micrographs taken after and 
before ephrinA5 treatment: whole 18­mm­diameter coverslips (equivalent to 100 low­magnification images; A) of phalloidin­stained cells were imaged by 
“tile scanning” on a fluorescence microscope. Mean ± SE from five separate experiments are shown (error bars; ***, P < 0.001; *, P < 0.05).1197 EphA3 regulation by PTP1B • Nievergall et al.
As expected, preclustered ephrinA5-Fc–induced EphA3 inter-
nalization caused a notable decrease in Alexa Fluor 594–monoSA 
fluorescence, providing a measure for the change in cell surface 
EphA3 levels (Fig. 8 B, ↔). Overexpression of either w/t   
PTP1B  or  PTP1B-[D-A]  in  these  cells  dose-dependently 
decreased this change, and thus the amount of internalizing 
EphA3 (Fig. 8 C). Likewise, overexpression of w/t PTP1B also 
decreased the trafficking of endogenous EphA3 in 22Rv1 pros-
tate carcinoma cells. In this case, the exogenous PTP1B-[D-A] in-
hibited ephrin-induced EphA3 endocytosis completely so that 
the EphA3 cell surface levels were increased after ephrinA5 
stimulation (Fig. 8 D). In control experiments, cell surface lev-
els of the constitutively recycling Transferrin transmembrane 
receptor were not influenced by exogenous PTP1B expression 
(Fig. S4 E), which argues against a global effect of PTP1B on 
receptor  recycling.  In  agreement  with  confocal  microscopic 
analysis (Fig. 8 A), these experiments suggest that both EphA3 
dephosphorylation by elevated w/t PTP1B, as well as binding 
of the PTP1B-[D-A]–trapping mutant likely blocking access 
to  EphA3-phospho-tyrosines,  markedly  attenuate  ephrinA5- 
induced EphA3 trafficking.
Discussion
Compelling evidence attests a crucial role of Ephs and ephrins 
in controlling cell–cell interactions during developmental cell 
positioning. Eph kinase signaling translates the ephrin cell sur-
face abundance into precisely graded changes in adhesion and 
position of the cells: high kinase activity triggers cell–cell repul-
sion, whereas lacking or low activity leads to tight cell adhesion 
(Lackmann and Boyd, 2008; Pasquale, 2008). Not surprisingly, 
a critical role of PTPs in controlling initiation and transduction 
of the underlying signals has been anticipated, but the spatial 
and temporal aspects of their recruitment into Eph signaling 
clusters have remained largely unexplored.
We  now  demonstrate  that  PTP1B,  a  ubiquitous  ER- 
resident phosphatase controlling the signaling of several growth 
factor receptors and cell adhesion proteins (Bourdeau et al., 
2005; Burridge et al., 2006; Sallee et al., 2006; Tonks, 2006), 
negatively regulates agonist-induced EphA3 phosphorylation. 
Unlike other RTKs, Ephs are activated in vivo only by surface-
tethered ephrins (Lackmann and Boyd, 2008; Pasquale, 2008), 
whereby, as we demonstrate here, PTP1B already interacts with 
activated cell-surface EphA3 before endocytosis, providing an 
example for a mechanism that allows the ER-tethered phospha-
tase to access its RTK substrates at sites of cell–cell contact 
(unpublished data). PTP1B activity has direct consequences 
on EphA3 receptor trafficking and downstream biological re-
sponses: PTP1B overexpression reduces EphA3 activation at 
the cell surface and in cytosolic compartments, thereby de-
creasing  ephrinA5-induced  cell  contraction,  whereas  PTP1B 
silencing enhances EphA3 activation and ephrin-induced cell 
contraction. Accordingly, pharmacological inhibition of EphA3 
kinase activation/signaling attenuates formation of boundar-
ies with ephrin-expressing cells, whereas inhibition of PTP1B 
activity and PTP1B silencing increases cell–cell repulsion and 
boundary formation.
area of cell cluster footprints, and reduced contacts (decreased 
branching) between cell clusters (Fig. 7, B and C). In agree-
ment, silencing of PTP1B in Eph
+ U251 cells also increased the 
segregation of the two cell populations and significantly reduced 
cell dispersion (Fig. S4, A and B), as revealed by significantly 
reduced numbers of fluorescence intensity peaks (Fig. S4 C).   
In contrast, treatment with an EphA3 kinase inhibitor signifi-
cantly increased the intermingling and cell dispersion between 
the two cell populations (Fig. 7 B and Fig. S3), as judged from 
decreased overall fluorescence intensity per area and an in-
creased branching ratio (Fig. 7 C). As expected, treatment with 
PTP1B  inhibitor  increased  EphA3  phosphorylation,  whereas 
EphA3 inhibitor treatment decreased it, which implies that their 
opposite effects on cell–cell segregation are likely caused by 
altered EphA3 activation (Fig. 7 D).
Collectively, these findings indicate that PTP1B, by control-
ling EphA3 phosphorylation, functions to modulate Eph-induced 
changes in cell morphology and cell–cell boundary formation.
PTP1B colocalizes with EphA3 and 
controls EphA3 trafficking
We next thought to examine cellular compartments and timing 
of  the  EphA3–PTP1B  interplay  during  ephrinA5-induced   
signaling and EphA3 trafficking. Previous studies demon-
strated rapid internalization of Eph/ephrin signaling complexes   
(Marston et al., 2003; Wimmer-Kleikamp et al., 2004; Janes   
et al., 2009), and costaining of ephrinA5-stimulated cells with 
antibodies against EphA3, endosomal (early endosomal antigen 
I [EEAI]), and lysosomal (LampI) markers revealed trafficking 
of activated EphA3 into the endosomal but not into the lyso-
somal compartment (Fig. S5, A and B). Interestingly in stimu-
lated,  GFP-PTP1B-[D-A]–expressing  cells,  PTP1B  also  was 
found colocalized with early endosomal vesicles, including those 
containing endocytosed EphA3 (Fig. S5 C).
Further analysis of GFP-PTP1B-[D-A]–transfected EphA3/ 
HEK293T cells (Fig. 8 A, top) and PTP1B
/ MEFs (Fig. S5 D)   
by confocal microscopy revealed both proteins at sites of cell–
cell contact. After ephrinA5 stimulation, GFP-PTP1B-[D-A]– 
and  EphA3-associated  fluorescence  also  notably  colocalized 
with endosomal vesicles (Fig. 8 A, top; and Fig. S5, A, C, and D).   
Live-cell imaging confirmed that internalization of Alexa Fluor 
594–ephrinA5–bound EphA3 and GFP-PTP1B-[D-A] con-
curred with cell contraction and detachment (Video 1). In ac-
cord with the perception that interactions between w/t PTPs 
and RTKs are transient, confocal analysis of cells transfected 
with w/t GFP-PTP1B did not allow detecting its colocalization   
with EphA3 (Fig. 8 A, bottom). However, closer inspection   
suggested that in cells with high w/t GFP-PTP1B, the levels of 
internalized EphA3 were markedly reduced compared with cells 
with low PTP1B expression (Fig. 8 A, closed and open arrow-
heads, respectively).
To evaluate this potential effect of PTP1B on ephrin- 
induced EphA3 trafficking quantitatively, we analyzed with flow 
cytometry APN-EphA3/BirA/HEK293T cells stably expressing 
constitutively biotinylated EphA3, allowing its rapid and explicit 
cell surface labeling with Alexa Fluor 594–tagged monovalent 
SA  (Alexa  Fluor  594–monoSA;  Howarth  and  Ting,  2008).   JCB • VOLUME 191 • NUMBER 6 • 2010   1198
Figure 7.  PTP1B activity affects Eph/ephrin-mediated cell segregation. (A) HEK293 and U251 cells were allowed to bind EphA3­Fc and ephrinA5­Fc, 
respectively, before labeling with Alexa Fluor 647–­human secondary antibodies and flow cytometry analysis. (B) Cell segregation was monitored in co­
cultures of U251 cells and cell tracker green–labeled HEK293 cells in the presence or absence of PTP1B inhibitor (10 µM PTP1B­I), EphA3 inhibitor (10 µM   
EphA3­I), or DMSO (as control for EphA3­I) for 72 h. Bright­field, fluorescence, and merged images of PFA fixed cell cultures are shown. Contour plots of 1199 EphA3 regulation by PTP1B • Nievergall et al.
(Yudushkin et al., 2007) and why extended residence at the cell 
surface prolongs EGF receptor phosphorylation (Offterdinger 
et al., 2004). For EphA3, our current evidence suggests that sig-
nal termination on endocytic vesicles is also facilitated through 
dephosphorylation by PTP1B.
ER-bound PTP1B (Frangioni et al., 1992) is thought to 
interact with transmembrane receptors mainly in the cytosol 
proximal to the ER (Haj et al., 2002; Boute et al., 2003) or after   
proteolytic release of the catalytic domain (Frangioni et al., 
1993; Cortesio et al., 2008), although it was reported recently 
that PTP1B can contact some transmembrane receptors and   
cell–matrix adhesion sites directly (Hernández et al., 2006;   
Anderie et al., 2007). In the case of EphA3, an RTK which gen-
erally requires contact with an ephrin-expressing cell for activa-
tion, cell surface interactions with PTP1B occur prominently   
at sites of cell–cell contact. However, stimulation with soluble 
ephrinA5 also enhanced EphA3/PTP1B interactions elsewhere 
on the cell surface and in endocytic vesicles, presumably because 
this nonphysiological activation triggers more immediate endo-
cytosis. In line with this argument, global phospho-proteomic 
analysis of Eph/ephrin signaling networks revealed significant 
qualitative and quantitative differences when cells were stimu-
lated with soluble, preclustered ephrins or by ephrin–cell contact 
(Jørgensen et al., 2009). It is likely that assembly of signaling 
clusters with interacting cell-bound ephrins results in a local 
accumulation of EphA3 that promotes interaction with PTP1B 
already at the cell surface. Indeed, our in vitro model of this sce-
nario, where tethered SA activates biotinylated EphA3 but can-
not be cleaved and thus prevents EphA3 from leaving the cell 
surface, confirms this notion. In this case, distinct PTP1B-[D-A]   
recruitment to biotinylated EphA3 is focused to the surface of 
SA-conjugated beads, which indicates that the PTP1B/EphA3   
interaction occurs before endocytosis. Thus, in agreement with 
its role in controlling EphA3 activation, trafficking, and signal-
ing, we demonstrate that ER-bound PTP1B-[D-A] can target 
phosphorylated cell surface EphA3 in areas of cell–cell contact 
before endocytosis, thereby directing the overall outcome of 
Eph/ephrin-facilitated cell–cell interactions.
Both EphA3 and PTP1B have documented roles in tumor 
development: PTP1B is implicated in growth and progression 
of solid tumors (Lessard et al., 2010), whereas unscheduled ex-
pression of Ephs and ephrins correlates with tumor progression 
in a range of highly invasive and metastatic tumors (Janes et al., 
2008) where EphA3 was identified as one of the genes most fre-
quently mutated in colon (Sjöblom et al., 2006) and lung cancer 
(Ding et al., 2008). In view of our findings here, the balance 
between Eph kinase and counteracting PTP1B activity is likely 
to be a critical regulatory mechanism for EphA3-mediated cell 
Eph receptors are activated in vivo within signaling clusters 
at the PM interface (Wimmer-Kleikamp et al., 2004) between Eph- 
and ephrin-expressing cells, and phosphorylation of the activation 
loop tyrosine, releasing the kinase from the Eph juxtamembrane 
segment, is required for full kinase activity (Wybenga-Groot   
et al., 2001; Wiesner et al., 2006). This conformational change 
relieves a steric hindrance, leading to functional association of the   
ADAM10 metalloprotease. This then facilitates ephrin shedding   
and endocytosis to proceed, which indicates that control of ki-
nase activity, ephrin shedding, and endocytosis are linked (Janes 
et al., 2009). In agreement with this notion, our findings here re-
veal that overexpression of PTP1B results in EphA3 dephos-
phorylation and dose-dependent reduction in trafficking of cell 
surface EphA3, which suggests direct control of phosphorylation- 
dependent endocytosis.
Notionally,  it  is  also  possible  that  the  observed  effect   
of PTP1B overexpression on cell surface EphA3 trafficking is 
caused by very rapid receptor recycling, as suggested for other 
transmembrane receptors (Grant and Donaldson, 2009); thus, 
PTP1B inhibition was shown to extend the presence of phos-
phorylated insulin receptor in the endocytic recycling compart-
ment (Cromlish et al., 2006). To date, the kinetics and mechanics 
of Eph endocytosis have remained largely unexplored, and a 
potential effect of PTP1B overexpression on EphA3 recycling 
clearly warrants further analysis. Nevertheless, the finding that 
phosphorylation of the activation loop tyrosine (EphA3-Y779), 
a recently identified PTP1B substrate (Mertins et al., 2008), is 
essential for ligand-induced endocytosis (Janes et al., 2009), 
together  with  our  observation  that  PTP1B  can  interact  with 
activated EphA3 at the PM, would suggest that elevated phos-
phatase levels and lack of EphA3 phosphorylation affect ephrin-
induced endocytosis directly. Overexpression of PTP1B-[D-A] 
has a very similar effect to w/t PTP1B and at high concentrations 
inhibits EphA3 internalization completely, though we argue for 
a different mechanism: its effective binding to phosphorylated 
EphA3 competitively blocks access to the phosphorylated acti-
vation loop tyrosine that is required for endocytosis.
The interaction with EphA3 and apparent phosphatase   
activity of PTP1B at sites of cell–cell contact and on endosomal 
vesicles raises important questions about the control of PTP1B 
activity in different cellular compartments. It is likely that, simi-
lar to other RTKs, EphA3 activation triggers ROS production 
and local inhibition of PTP activity, which is gradually reversed 
once the endosomes have traveled into the cytosol. In the case 
of EGF and insulin receptors, where dephosphorylation by PTP1B 
occurs en route past the ER (Haj et al., 2002; Boute et al., 2003), 
an increase in PTP1B activity toward the nucleus explains why 
RTK  phosphorylation  declines  with  increasing  PM  distance 
cell tracker green fluorescent images were generated (MatLab) to illustrate the accumulation of HEK293 cells and the effects of the inhibitor on sorting of 
mixed HEK293 and U251 cell populations (bottom); their quantification is shown in Fig. S3. (C) Additional quantification of the segregation assay was 
performed by analyzing ratios of overall fluorescence intensity/area, and the branching ratio of fluorescent areas using ImageJ software. For each setting, 
cell tracker green images equivalent to 60 fields of view (as shown in B) were analyzed for n = 3 independent experiments. Mean ± SE are shown (error 
bars; **, P < 0.01; ***, P < 0.001). (D) Co­cultures of HEK293 and U251 cells were treated with PTP1B or EphA3 inhibitor as indicated for 48 h. Lysates 
and ­EphA3 immunoprecipitates were subjected to Western blot analysis with the appropriate antibodies. Levels of phosphorylated EphA3 relative to total 
expression were determined by densitometry. Data are representative of at least two independent experiments. Molecular mass standards are indicated 
next to the gel blots in kilodaltons.
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control of Eph/ephrin-facilitated cell positioning by modulat-
ing the balance between phosphorylated and dephosphorylated 
Ephs  during  embryonic  as  well  as  oncogenic  development.   
In support of the underlying notion that PTP1B may also regu-
late activity of other Ephs, our FRET analysis also suggested a 
positioning during tumor development and progression. In line   
with emerging evidence for a role of PTP1B in cell spreading, 
migration, and cancer cell invasion (Arregui et al., 1998; Cortesio 
et al., 2008), we propose that, similar to PTPRO in neuronal 
cells (Shintani et al., 2006), PTP1B acts as cell-autonomous 
Figure 8.  Elevated expression of w/t PTP1B 
or  PTP1B-[D-A]  inhibits  EphA3  endocytosis. 
(A) EphrinA5­Fc stimulated (10 min) EphA3/
HEK293T  cells  expressing  exogenous  GFP­
PTP1B­[D­A]  or  w/t  GFP­PTP1B  were  fixed, 
permeabilized, and labeled with ­EphA3 and 
Alexa Fluor 546–labeled secondary antibod­
ies for confocal microscopy. Individual fluores­
cent channels and merged images are shown. 
Closed  and  open  arrowheads  denote  cells 
with highly elevated and low levels of PTP1B, 
respectively. Areas of interest are boxed and 
shown  at  increased  magnification  (insets).   
(B) The level of biotinylated EphA3 on the sur­
face  of  APN­EphA3/TM­BirA/HEK293T  cells 
was determined by flow cytometry using Alexa 
Fluor  594–monoSA.  The  Alexa  Fluor  594– 
monoSA intensity of ephrin­stimulated (20 min) 
cells is reduced compared with untreated cells, 
which  reflects  EphA3  internalization  (↔). 
(C)  The  relative  ephrinA5­induced  change 
in cell surface EphA3 was determined as in 
B  in  cells  transfected  with  pEGFP  (control),   
w/t GFP­PTP1B, or GFP­PTP1B–[D­A] at cDNA 
concentrations of 0.15, 0.3, or 0.6 µg/well 
as indicated. Mean ± SE from three individual 
samples from each condition are shown (error 
bars). (D) 22Rv1 cells transfected with EGFP, 
GFP­PTP1B­[D­A],  or  w/t  GFP­PTP1B  were 
stimulated with ephrinA5­Fc for 20 min, and 
cell surface EphA3 was labeled using sheep 
­EphA3  and  Alexa  Fluor  647  secondary 
antibodies, analyzed by flow cytometry, and 
evaluated as described in B. Mean ± SE from 
six  individual  samples  of  two  separate  ex­
periments are shown (error bars; *, P < 0.05; 
***, P < 0.001).1201 EphA3 regulation by PTP1B • Nievergall et al.
Stable ephrinA5 (ephrinA5/HEK293T)­expressing cell clones have been   
described previously (Janes et al., 2005). NG108 cells (mouse neuro­
blastoma × rat glioma hybrid) were provided by T. Pawson (Mount Sinai 
Hospital, Toronto, Canada) and maintained in DME, 10% FCS, and 1× HAT 
supplement (Invitrogen). Human prostate carcinoma 22Rv1 cells (American 
Type Culture Collection) were maintained in RPMI 1640/10% FCS.
Transfections and gene knockdown by RNA interference
Transfections of cDNA were performed with Lipofectamine 2000 (Invitro­
gen) or FugeneHD (Roche) according to the manufacturer’s instructions. 
PTP1B silencing was achieved using the Mission Lentiviral Transduction 
Particles system (Sigma­Aldrich) according to the manufacturer’s instruc­
tions. Four different hairpin constructs in individual lentivirus clones for 
PTP1B silencing as well as nontarget control lentivirus particles were used 
to create stable cell lines by puromycin­induced killing (1 µg/ml for 22Rv1, 
2 µg/ml for EphA3/HEK293T) of nontransduced cells.
Ephrin stimulation, immunoprecipitation, and Western blotting
For ligand stimulation, ephrinA5­Fc (1.5 µg/ml final) was preclustered using   
goat anti–human IgG (Fc­specific) and applied to the cells for 10 min or as 
indicated. Whole cell lysis was performed in 50 mM Tris, pH 7.4, 150 mM   
NaCl, 1% Triton X­100, 0.1% SDS, 1 mM NaV04, 10 mM NaF, and pro­
tease inhibitors (Complete; Roche). EphA3 was immunoprecipitated from 
cell lysates with mAb IIIA4 conjugated to Mini­Leak beads (Kem­En­Tec) as 
described previously (Janes et al., 2005). Immunoprecipitates or whole cell 
lysates were analyzed by Western blotting with appropriate antibodies, 
and blots were visualized using an ECL substrate (Supersignal; Thermo 
Fisher Scientific).
Flow cytometry and internalization assay
HEK293 and U251 cells were detached using 0.5 mM EDTA/PBS and in­
cubated with EphA3­Fc or ephrinA5­Fc in FACS buffer (1% FCS, 0.5 mM 
EDTA in PBS) for 30 min on ice before washing and labeling with Alexa 
Fluor 647–­human secondary antibodies. Flow cytometry was performed 
on an LSRII (BD), and data were analyzed using FlowJo (Tree Star, Inc.).
To assess EphA3 internalization, HEK293T cell clones expressing 
biotinylated  EphA3  (APN­EphA3/TM­BirA/HEK293T)  were  transfected 
with PTP1B cDNA as indicated, then treated with preclustered ephrinA5­Fc 
for 20 min followed by labeling with Alexa Fluor 594–monoSA in FACS 
buffer for 30 min at 4°C. 22Rv1 cells were transfected and stimulated 
in the same manner, and cell surface levels of endogenous EphA3 were 
labeled with sheep ­EphA3 pAb followed by an Alexa Fluor 647 second­
ary antibody.
Cell sorting assay
HEK293 cells were mixed with U251 cells at a ratio of 2:1. Cells were 
differentiated by labeling one population with CellTracker green according 
to the manufacturer’s instructions (Invitrogen) and cultured at a density of 
55,000 cells/cm
2 (100,000 cells/ml media) to reach confluency within   
3 d. Cells fixed in 4% paraformaldehyde were imaged in PBS at 37°C on 
an inverted microscope (AF6000LX; Leica) equipped with a camera (DFC 
350FX; Leica) and running LAS AF software using a 10× dry objective   
(NA 0.3) and a monochromator (Leica).
ImageJ was used to threshold and process the fluorescent images   
for subsequent analysis with a MATLAB (MathWorks Inc.) script (see sup­
plemental material) to graph the fluorescence intensity as 3D contour maps 
and to quantitate the area (in pixels) and fluorescence intensity of individ­
ual peaks (representing cell aggregates) above a baseline intensity as a 
measure of cell sorting. In this context, cell sorting was regarded as loss of 
cell dispersion and is quantitated as a reduction in the number of small fluores­
cence intensity peaks in microscopic sections (0.4–0.8 mm
2) randomly se­
lected from a minimum of n = 4 independent experiments (a representative 
image from each group is shown). In addition, lower magnification images 
were captured using a 4× objective (NA 0.16) on a wide­field fluorescence 
microscope  (Cell­R;  Olympus)  equipped  with  a  charge­coupled  device   
camera (XM10) and Cell­R image acquisition software (Olympus). These   
images were analyzed using ImageJ and AnalyzeSkeleton (Ignacio Arganda­ 
Carreras, Massachusetts Institute of Technology, Cambridge, MA) plug­ins 
to determine the overall intensity/area ratio and degree of branching of 
fluorescent areas, respectively.
Confocal and wide-field fluorescence microscopy
Cells on coverslips, transfected and treated as indicated, were fixed in 4% 
paraformaldehyde (or methanol for FG6 mAb labeling), permeabilized in 
0.1% Triton X­100/PBS, labeled with antibody or phalloidin (rhodamine­ 
or Alexa Fluor 647–labeled) as indicated, and mounted in Mowiol (EMD). 
direct interaction of the PTP1B substrate-trapping mutant with 
activated EphB2.
In summary, our study provides detailed molecular and 
mechanistic insights into phosphatase-controlled Eph receptor 
activation, trafficking, and cellular responses. We demonstrate 
for the first time that PTP1B is a principal regulator of EphA3 
activity and function, and controls the steady-state concentra-
tion of cell surface EphA3. In view of emerging evidence for 
crosstalk between Ephs and other RTKs and adhesion recep-
tors (Lackmann and Boyd, 2008; Pasquale, 2008), our find-
ing that ER-tethered PTP1B interacts with activated EphA3 at 
the cell surface may suggest that activated Ephs are among the 
PTP1B substrates that polarize the ER toward the PM and pro-
vide PTP1B access to areas of cell–cell contacts (unpublished 
data). Importantly, we confirm that the crucial Eph-mediated 
switch between cell–cell repulsion and adhesion is controlled 
by the activity of Eph-specific PTPs such as PTP1B. Further 
elucidation of the mechanisms that shift the balance between 
dominating PTP and dominating Eph activity will impact sig-
nificantly on our understanding of Eph function in normal and 
oncogenic development.
Materials and methods
Expression constructs
Mammalian pEFBos expression vectors for full­length EphA3, EphA3­GFP, 
and APN­EphA3 have been described previously (Wimmer­Kleikamp et al., 
2004), and deletions and point mutations were made using site­directed 
mutagenesis  (QuikChange  XL;  Agilent  Technologies).  EphA3­YFP  was 
constructed by replacing the GFP sequence with YFP cDNA. Membrane­ 
targeted BirA (TM­BirA) was generated from YFP­tagged TM­BirA (from   
A. Ting, Massachusetts Institute of Technology, Cambridge, MA). Fluorescent 
protein­tagged PTP1B expression constructs have been described previously 
(Haj et al., 2002). PTP1B and TC­PTP w/t and [D­A]­trapping mutants in 
pMT2 were provided by T. Tiganis (Monash University, Melbourne, Australia) 
and described previously (Flint et al., 1997; Tiganis et al., 1998).
Reagents and antibodies
Production of ephrinA5­Fc, Alexa Fluor 546–ephrinA5–Fc, EphA3­Fc, and   
the  ­EphA3  mAb  (IIIA4)  have  been  described  previously  (Lawrenson   
et al., 2002; Wimmer­Kleikamp et al., 2008). Antigen affinity­purified sheep 
­EphA3 was used for immunoblots. PTP1B mAbs were AE4­2J (EMD) for 
immunoblots and FG6 (Haj et al., 2002) for immunocytochemistry. Cy5­
FG6 and Cy3.5­PY72 (Reynolds et al., 2003) were labeled using a ­Cy5 
or Cy3.5 mono­Reactive Dye Pack (GE Healthcare). TC­PTP mAb (CF4) 
was provided by T. Tiganis. Other antibodies were obtained from Invitro­
gen (rabbit ­PY), Thermo Fisher Scientific (­actin), Abcam (­EEAI), BD 
(­LampI; ­Transferrin receptor), Roche (­GFP), and Millipore (­phospho­ 
EphA3). All HRP­labeled secondary antibodies for Western blotting and 
anti­human  Fc  were  obtained  from  Jackson  ImmunoResearch  Laborato­
ries, except ­mouse­HRP (GE Healthcare) and ­sheep­HRP (Millipore). 
Alexa Fluor–labeled secondary antibodies and rhodamine­ or Alexa Fluor 
647–phalloidin  were  obtained  from  Invitrogen.  MonoSA  (provided  by   
A. Ting) was labeled with Alexa Fluor 594 (Invitrogen). Difluoromethyl­
phosphonate PTP1B inhibitor (Han et al., 2008) was provided by B. Kennedy 
and K. McCusker (Merck Frosst Canada, Kirkland, Quebec, Canada), and 
EphA3 kinase inhibitor (Choi et al., 2009) was a gift of N. Gray (Harvard 
Medical School, Boston, MA).
Cell culture
Human kidney epithelial 293T (HEK293T), COS7 African green monkey 
kidney fibroblast cell line, U251 human glioblastoma cells (provided by   
A.  Scott,  Ludwig  Institute  For  Cancer  Research,  Melbourne  Centre  for 
Clinical Sciences, Melbourne, Australia), PTP1B­deficient MEFs, and cor­
responding  w/t  PTP1B  reconstituted  cell  lines  (Haj  et  al.,  2003)  were 
maintained in DME supplemented with 10% FCS. Stable HEK293T and 
MEF cell lines expressing APN­EphA3 alone or with TM­BirA were gener­
ated through clonal selection (0.2 mg/ml zeocin and 400 µg/ml G418). JCB • VOLUME 191 • NUMBER 6 • 2010   1202
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